Assetmark, Inc Alnylam Pharmaceuticals, Inc. Transaction History
Assetmark, Inc
- $45.6 Billion
- Q3 2025
A detailed history of Assetmark, Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Assetmark, Inc holds 11,918 shares of ALNY stock, worth $5.25 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
11,918
Previous 11,543
3.25%
Holding current value
$5.25 Million
Previous $3.76 Million
44.37%
% of portfolio
0.01%
Previous 0.01%
Shares
19 transactions
Others Institutions Holding ALNY
# of Institutions
830Shares Held
115MCall Options Held
584KPut Options Held
648K-
Capital World Investors Los Angeles, CA16.8MShares$7.4 Billion0.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$5.86 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.21 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.19MShares$3.17 Billion0.49% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.28MShares$1.89 Billion0.88% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $54.2B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...